417 related articles for article (PubMed ID: 7606734)
1. Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors.
Stein R; Goldenberg DM; Thorpe SR; Basu A; Mattes MJ
Cancer Res; 1995 Jul; 55(14):3132-9. PubMed ID: 7606734
[TBL] [Abstract][Full Text] [Related]
2. Targeting human cancer xenografts with monoclonal antibodies labeled using radioiodinated, diethylenetriaminepentaacetic acid-appended peptides.
Stein R; Govindan SV; Mattes MJ; Shih LB; Griffiths GL; Hansen HJ; Goldenberg DM
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3079s-3087s. PubMed ID: 10541347
[TBL] [Abstract][Full Text] [Related]
3. Advantage of a residualizing iodine radiolabel for radioimmunotherapy of xenografts of human non-small-cell carcinoma of the lung.
Stein R; Goldenberg DM; Thorpe SR; Mattes MJ
J Nucl Med; 1997 Mar; 38(3):391-5. PubMed ID: 9074526
[TBL] [Abstract][Full Text] [Related]
4. Improved iodine radiolabels for monoclonal antibody therapy.
Stein R; Govindan SV; Mattes MJ; Chen S; Reed L; Newsome G; McBride BJ; Griffiths GL; Hansen HJ; Goldenberg DM
Cancer Res; 2003 Jan; 63(1):111-8. PubMed ID: 12517786
[TBL] [Abstract][Full Text] [Related]
5. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo reactivity of an internalizing antibody, RS7, with human breast cancer.
Shih LB; Xuan H; Aninipot R; Stein R; Goldenberg DM
Cancer Res; 1995 Dec; 55(23 Suppl):5857s-5863s. PubMed ID: 7493360
[TBL] [Abstract][Full Text] [Related]
7. Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel.
Govindan SV; Stein R; Qu Z; Chen S; Andrews P; Ma H; Hansen HJ; Griffiths GL; Horak ID; Goldenberg DM
Breast Cancer Res Treat; 2004 Mar; 84(2):173-82. PubMed ID: 14999147
[TBL] [Abstract][Full Text] [Related]
8. Comparative biodistribution and radioimmunotherapy of monoclonal antibody RS7 and its F(ab')2 in nude mice bearing human tumor xenografts.
Stein R; Blumenthal R; Sharkey RM; Goldenberg DM
Cancer; 1994 Feb; 73(3 Suppl):816-23. PubMed ID: 8306265
[TBL] [Abstract][Full Text] [Related]
9. 90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal biodistribution studies.
Govindan SV; Shih LB; Goldenberg DM; Sharkey RM; Karacay H; Donnelly JE; Losman MJ; Hansen HJ; Griffiths GL
Bioconjug Chem; 1998; 9(6):773-82. PubMed ID: 9815172
[TBL] [Abstract][Full Text] [Related]
10. Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct.
Pavlinkova G; Booth BJ; Batra SK; Colcher D
Clin Cancer Res; 1999 Sep; 5(9):2613-9. PubMed ID: 10499640
[TBL] [Abstract][Full Text] [Related]
11. Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts.
Sharkey RM; Motta-Hennessy C; Pawlyk D; Siegel JA; Goldenberg DM
Cancer Res; 1990 Apr; 50(8):2330-6. PubMed ID: 2180566
[TBL] [Abstract][Full Text] [Related]
12. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22.
Sharkey RM; Behr TM; Mattes MJ; Stein R; Griffiths GL; Shih LB; Hansen HJ; Blumenthal RD; Dunn RM; Juweid ME; Goldenberg DM
Cancer Immunol Immunother; 1997 May; 44(3):179-88. PubMed ID: 9191878
[TBL] [Abstract][Full Text] [Related]
13. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
14. Advantage of a residualizing iodine radiolabel in the therapy of a colon cancer xenograft targeted with an anticarcinoembryonic antigen monoclonal antibody.
Stein R; Govindan SV; Hayes M; Griffiths GL; Hansen HJ; Horak ID; Goldenberg DM
Clin Cancer Res; 2005 Apr; 11(7):2727-34. PubMed ID: 15814655
[TBL] [Abstract][Full Text] [Related]
15. Labeling of monoclonal antibodies with diethylenetriaminepentaacetic acid-appended radioiodinated peptides containing D-amino acids.
Govindan SV; Mattes MJ; Stein R; McBride BJ; Karacay H; Goldenberg DM; Hansen HJ; Griffiths GL
Bioconjug Chem; 1999; 10(2):231-40. PubMed ID: 10077472
[TBL] [Abstract][Full Text] [Related]
16. Residualizing iodine markedly improved tumor targeting using bispecific antibody-based pretargeting.
van Schaijk FG; Broekema M; Oosterwijk E; van Eerd JE; McBride BJ; Goldenberg DM; Corstens FH; Boerman OC
J Nucl Med; 2005 Jun; 46(6):1016-22. PubMed ID: 15937314
[TBL] [Abstract][Full Text] [Related]
17. Targeting strategies for cancer radiotherapy.
Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
[TBL] [Abstract][Full Text] [Related]
18. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts.
Reist CJ; Archer GE; Kurpad SN; Wikstrand CJ; Vaidyanathan G; Willingham MC; Moscatello DK; Wong AJ; Bigner DD; Zalutsky MR
Cancer Res; 1995 Oct; 55(19):4375-82. PubMed ID: 7671250
[TBL] [Abstract][Full Text] [Related]
19. Comparative biodistributions of yttrium- and indium-labeled monoclonal antibody B72.3 in athymic mice bearing human colon carcinoma xenografts.
Roselli M; Schlom J; Gansow OA; Raubitschek A; Mirzadeh S; Brechbiel MW; Colcher D
J Nucl Med; 1989 May; 30(5):672-82. PubMed ID: 2785585
[TBL] [Abstract][Full Text] [Related]
20. Advantage of yttrium-90-labeled over iodine-131-labeled monoclonal antibodies in the treatment of a human lung carcinoma xenograft.
Stein R; Chen S; Haim S; Goldenberg DM
Cancer; 1997 Dec; 80(12 Suppl):2636-41. PubMed ID: 9406718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
